Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 304223
The Inventions and Technologies licensed relate to the ABBIE patent estate that includes patent families. One such family is titled â€œNovel Nanoparticleâ€“Based Vaccine Targeting Cancer/Testis Antigens (CTA) and itsâ€™ Use in Solid and Hematological Malignanciesâ€. The use and methods for a vaccine composition comprising of particles comprising nanoparticles, microparticles or a mixture thereof.
ABBIE is a non-viral gene editing mechanism to insert the target DNA template information into the T cell genome at a precise, predetermined locus. ABBIE allows the creation of the plasmid (â€œglueâ€) that goes through the membrane to the nucleus and inserts the genome template into the T cells so that they could express the CAR T protein and possibly other accessory proteins while possibly eliminating unwanted inhibitory proteins.
The license granted is for the inventions and technologies for the use of oral vaccines for any diseases, including, without limitation, any form of cancer.
IPSCIO Record ID: 356264
IPSCIO Record ID: 305790
Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.
The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.
XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.
The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.
Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.
IPSCIO Record ID: 345200
For clarification, the University has the right to grant exclusive licenses to third parties under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine and to develop and perform Licensed Processes solely to develop, make, have made, use, sell, offer to sell, lease and import any product that is solely a therapeutic or prophylactic vaccine.
License Grants, of the License Agreement shall be amended to read in its entirety as follows
The University grants to Company a license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Therapeutic Licensed Products and Diagnostic Licensed Products in the Disease Field; develop, make, have made, use, sell, offer to sell, lease, and import Reagent Licensed Products; and develop and perform Licensed Processes except, solely, to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine, unless earlier terminated per the terms of this Agreement.
In order to establish an exclusive period for Company and University agrees that it shall not grant any other license under the Patent Rights (except University Sub 100Nm Biodegradable Polymer Spheres Capable Of Releasing Nucleic Acids) to develop, make, have made, use, sell, offer to sell, lease or import Therapeutic Licensed Products or Diagnostic Licensed Products in the Disease Fields in the Territory during the Term, or to develop or perform Licensed Processes, other than solely to develop, make, have made, use, sell, offer to sell, lease, or import any product that is solely a therapeutic or prophylactic vaccine, in the Disease Fields in the Territory during the Term, unless earlier terminated per the terms of this Agreement.